Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Non-Hodgkin's lymphoma

D G Maloney1

  • 1Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.

Current Opinion in Hematology
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Non-Hodgkin's lymphoma incidence is rising, with age-related molecular changes potentially indicating early malignancy. Advances include new classifications and treatments, though challenges remain in aggressive lymphoma therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion.

Nature communications·2024
Same author

An algorithm for suboptimally placed supraglottic airway devices: the choice of videolaryngoscope.

British journal of anaesthesia·2017
Same author

CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.

Clinical pharmacology and therapeutics·2016
Same author

Residual neuromuscular blockade and tracheal extubation in recovery rooms - a reply.

Anaesthesia·2015
Same author

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Leukemia·2015
Same author

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bone marrow transplantation·2015
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Rising incidence of non-Hodgkin's lymphoma (NHL).
  • Age-related molecular changes in lymphocytes may precede malignant transformation.
  • Need for updated classification and treatment strategies for NHL.

Purpose of the Study:

  • To review current understanding and advancements in non-Hodgkin's lymphoma.
  • To discuss new classification systems and identified entities.
  • To evaluate therapeutic approaches and their outcomes.

Main Methods:

  • Analysis of molecular, immunophenotypic, and histologic data.
  • Review of clinical trial outcomes for various therapeutic regimens.
  • Assessment of treatment effects on localized and advanced lymphoma.

Related Experiment Videos

Main Results:

  • New classification system proposed with identified NHL entities.
  • Radiotherapy effective for localized low-grade NHL; extensive disease has a relapsing course.
  • Current therapies cure <50% of advanced aggressive lymphoma; high-dose therapy may benefit high-risk subsets.
  • Donor T-cell therapy shows promise for post-transplantation lymphoproliferative disorders.

Conclusions:

  • Ongoing research is crucial for improving NHL treatment outcomes.
  • High-dose therapy warrants further investigation for specific patient groups.
  • Novel approaches like donor T-cell therapy offer new avenues for challenging lymphoid disorders.